Pulmonary toxicities of molecular targeted antineoplastic agents: a single-center 10-year experience
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: A better understanding of cancer cell biology has led to the discovery and development of several new targeted agents for cancer. These drugs are widely used in cancer treatment and have good toxicity profiles. However, some patients are extremely sensitive to these drugs and can develop severe toxicities. Among the toxicities, pulmonary complications are infrequent with most targeted therapies. This study aimed to identify the radiologic pulmonary complications in various targeted therapies and to analyze the characteristics of patients with pulmonary toxicity. Methods: We retrospectively reviewed the medical records and chest image findings of 644 patients who were treated with targeted antineoplastic agents at Soonchunhyang University Hospital between May 2005 and September 2014. Results: Of these 644 patients, 90 (14.0%) developed pulmonary complications as noted on chest computed tomography. Among these patients, 15 (2.3%) developed drug-related pulmonary toxicities. Treatment with targeted agents was discontinued in all patients, while 11 patients were simultaneously treated with glucocorticoids. Three patients died of drug-related pulmonary toxicity. Conclusions: During targeted therapy, clinicians should assess for pulmonary toxicities and symptoms that occur with dyspnea. If drug-induced pulmonary toxicities are suspected, imaging studies should be performed immediately, and the possibility of variable radiological patterns should be considered. Discontinuing the use of implicated causative agents and treatment with glucocorticoids resulted in an improvement in both symptoms and imaging findings, but some patients still experienced fatal pulmonary toxicities.
Abstract
Background/Aims: A better understanding of cancer cell biology has led to the discovery and development of several new targeted agents for cancer. These drugs are widely used in cancer treatment and have good toxicity profiles. However, some patients are extremely sensitive to these drugs and can develop severe toxicities. Among the toxicities, pulmonary complications are infrequent with most targeted therapies. This study aimed to identify the radiologic pulmonary complications in various targeted therapies and to analyze the characteristics of patients with pulmonary toxicity. Methods: We retrospectively reviewed the medical records and chest image findings of 644 patients who were treated with targeted antineoplastic agents at Soonchunhyang University Hospital between May 2005 and September 2014. Results: Of these 644 patients, 90 (14.0%) developed pulmonary complications as noted on chest computed tomography. Among these patients, 15 (2.3%) developed drug-related pulmonary toxicities. Treatment with targeted agents was discontinued in all patients, while 11 patients were simultaneously treated with glucocorticoids. Three patients died of drug-related pulmonary toxicity. Conclusions: During targeted therapy, clinicians should assess for pulmonary toxicities and symptoms that occur with dyspnea. If drug-induced pulmonary toxicities are suspected, imaging studies should be performed immediately, and the possibility of variable radiological patterns should be considered. Discontinuing the use of implicated causative agents and treatment with glucocorticoids resulted in an improvement in both symptoms and imaging findings, but some patients still experienced fatal pulmonary toxicities.
참고문헌 (21)
- Barber NA, "Pulmonary toxicities from targeted therapies : a review", Target Oncol, 6, pp.235~243 (2011)
- Aparicio G, "Comprehensive lung injury pathology induced by mTOR inhibitors", Clin Transl Oncol, 11, pp.499~510 (2009)
- Arora A, "Role of tyrosine kinase inhibitors in cancer therapy", J Pharmacol Exp Ther, 315, pp.971~979 (2005)
- Burton C, "Interstitial pneumonitis related to rituximab therapy", N Engl J Med, 348, pp.2690~2691 (2003)
- 강원석, "Nonspecific Interstitial Pneumonitis after Bortezomib and Thalidomide Treatment in a Multiple Myeloma Patient", Yonsei Medical Journal, 51(3), pp.448~450 (2010), 연세대학교의과대학
- Makris D, "Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer", BMC Cancer, 7, pp.150~ (2007)
- Vahid B, "Pulmonary complications of novel antineoplastic agents for solid tumors", Chest, 133, pp.528~538 (2008)
- Vulsteke C, "Rituximab-induced fatal interstitial pneumonitis : case report", Leuk Lymphoma, 51, pp.546~548 (2010)
- Austin JH, "Glossary of terms for CT of the lungs : recommendations of the Nomenclature Committee of the Fleischner Society", Radiology, 200, pp.327~331 (1996)
- Hansell DM, "Fleischner Society : glossary of terms for thoracic imaging", Radiology, 246, pp.697~722 (2008)
- Kang HJ, "Adverse pulmonary reactions associated with the use of monoclonal antibodies in cancer patients", Respir Med, 106, pp.443~450 (2012)
- 범승훈, "Gefitinib-Induced Interstitial Lung Disease in Korean Lung Cancer Patients", Cancer Research and Treatment, 48(1), pp.88~97 (2016), 대한암학회[DOI]
- Inoue A, "Severe acute interstitial pneumonia and gefitinib", Lancet, 361, pp.137~139 (2003)
- Peerzada MM, "Pulmonary toxicities of tyrosine kinase inhibitors", Clin Adv Hematol Oncol, 9, pp.824~836 (2011)
- Min JH, "Drug-induced interstitial lung disease in tyrosine kinase inhibitor therapy for nonsmall cell lung cancer : a review on current insight", Cancer Chemother Pharmacol, 68, pp.1099~1109 (2011)
- Dimopoulou I, "Pulmonary toxicity from novel antineoplastic agents", Ann Oncol, 17, pp.372~379 (2006)
- Rossi SE, "Pulmonary drug toxicity : radiologic and pathologic manifestations", Radiographics, 20, pp.1245~1259 (2000)
- Domingo C, "Neglected respiratory toxicity caused by cancer therapy", Open Respir Med J, 1, pp.1~6 (2007)
- Takano T, "Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib", Lung Cancer, 45, pp.93~104 (2004)
- Ando M, "Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib", J Clin Oncol, 24, pp.2549~2556 (2006)
- Higenbottam T, "Understanding the mechanisms of drug-associated interstitial lung disease", Br J Cancer, 91(Suppl 2), pp.S31~S37 (2004)